Anavex Life Sciences Corp (OTCMKTS:AVXL) is a prominent firm in the segment of biopharmaceuticals. The company formulates the drugs to treat Alzheimer and several other CNS problems. Recently, it announced that it now had Jacqueline French added to its Scientific Advisory Board. It is a moment of honor as she is a renowned expert and have deep knowledge of therapeutic interventions, epilepsy treatments and clinical trial methodology.
Strengthening the team
The CEO of Anavex, Christopher U. Missling, expressed that the board is delighted to have French as a Scientific Advisor. Her contribution in field of medical world especially in epilepsy treatments has been significant. The company stated that she is recognized for leading the clinical treatment of seizures. The management is confident French’s expertise and experience in neurology will help in meeting the defined goals.
Anavex Life Sciences Corp (OTCMKTS:AVXL) stated that Dr. French is an influential personality and plays a leadership role in the segment of formulation of new as well as effective therapeutics for epilepsy. Her work is not only limited to therapies but also looks after symposium on trial design. She has been serving on the key positions on committees of the reputed AAN, where she co-authored AAN clinical practice guidelines. She has written research articles, effective editorials and chapters. Her articles have been published in world-famous publications. She edited books focused on epilepsy. Apart from author she is also a global presenter on topics like antiepileptic drug therapeutics.
Dr. French is highly impressed with the positive results on ANAVEX 2-73, which reflects a substantial reduction in anti-seizure effectiveness. The treatment findings are much better and encouraging. As of now, there are three accepted epilepsy medications. The medication has proved harmless in the first phase trial and is supportive of upcoming next-general epilepsy treatments. She will work together with the team of scientific advisors.